Home › Funds › Propel Bio Management, LLC › SABS

Propel Bio Management, LLC position in SABS

SAB Biotherapeutics Inc · Health Care

Propel Bio Management, LLC reported holding 1,187,422 shares of SABS (SAB Biotherapeutics Inc) in its Q3 2026 13F filing — a position valued at US$3.8M, representing 2.00% of its reported portfolio and ranking #17 among its reported holdings. Propel Bio Management, LLC has disclosed SABS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.19M sh
Reported value held$3.76M
Portfolio Weight2.00%
First reportedQ4 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Propel Bio Management, LLC's SABS position evolved

Propel Bio Management, LLC first disclosed a stake in SABS in Q4 2025 at 652,881 shares (US$2.4M). The position peaked in Q2 2026 at 1,076,578 shares, worth US$4.2M. Across 4 filings, Propel Bio Management, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,187,422 shares valued at US$3.8M — an increase of 110,844 shares quarter over quarter.. Notable position changes include a 55% increase in Q1 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 652.88K $2.44M New
Q1 2026 1.01M $3.89M Add
Q2 2026 1.08M $4.20M Add
Q3 2026 1.19M $3.76M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SABS and 13F data

SABS (SAB Biotherapeutics Inc) is a Health Care company. 71 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$21.9M), Commodore Capital LP (US$11.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SABS

All SABS fund holders →

FAQ

How long has Propel Bio Management, LLC held SABS?

Propel Bio Management, LLC has disclosed SABS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Propel Bio Management, LLC's current position in SABS?

As of Q3 2026, Propel Bio Management, LLC holds 1.19M shares of SABS (SAB Biotherapeutics Inc), valued at $3.76M, representing 2.00% of its reported portfolio and ranking #17.

Has Propel Bio Management, LLC been buying or selling SABS?

In the latest 13F filing (Q3 2026), Propel Bio Management, LLC increased its position in SABS. The position peaked in Q2 2026 at 1.08M shares.

Which other funds hold SABS?

Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Commodore Capital LP, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.